All participants were informed about the study design and then written informed consent was obtained from all volunteers
The statements regarding these products have not been evaluated by the FDA
Disclosure of interest: KEVIN ROYCE ANG: NOTHING TO DISCLOSE E-Posters - ACUTE ISCHEMIC STROKE MANAGEMENT 01.00 - ACUTE ISCHEMIC STROKE MANAGEMENT - 01.02 - ACUTE MANAGEMENT - Thrombolysis or thrombectomy P2003 - ESOC25-95 ASSOCIATION OF CTP PARAMETERS WITH OUTCOMES IN PATIENTS WITH MEDIUM VESSEL OCCLUSION UNDERGOING THROMBECTOMY Yoel Schwartzmann 1 , Hamza Joubran 1 , Tamer Jubeh 1 , Issa Metanis 1 , Aviva Alpernas 2 , Tali Jonas Kimchi 2 , Udi Sadeh 2 , John Moshe Gomori 1 , Jose Cohen 1 , Hen Hallevi 2 , Jeremy Molad 2 , Ronen R Leker 1 1 Hadassah-Hebrew University Medical Center, Jerusalem, Israel, 2 Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel Background and Aims: Imaging biomarkers obtained on CT perfusion (CTP) have proven effective in predicting outcomes after EVT in patients with large vessel occlusion stroke

FOXO4-DRI (Proxofim) 10mg CAS: N/A FOXO4 DRI 10 mg Proxofim by Biopeptides is a cutting-edge research peptide designed for advanced studies in cellular senescence, apoptosis, and aging biology
After reconstitution: Store at 2-8C and use within 30 days
5-alpha reductase (5-AR) is an enzyme found in hair follicles, the prostate, liver, and skin